6.Zou Z,et al. Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort. Transl Lung Cancer Res. 2022 Dec;11(12):2495...
[3]Chouaid C, Dujon C, Do P, et al. Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01)[J]. Lun...
In February this year, Alkut climbed Siguniang Mountain in Sichuan"及第三段中的“On May 19, Alkut finally reached the top of the world"可知,他8 岁时学会了滑雪,去年7月 份,他和爸爸攀登了新疆的慕士塔格峰,今年2月份攀登 了四川的四姑娘山。 在5月19日终于登上了世界之巅。 故选C。 3C 落...
He arrived at the South Base Camp in Nepal on April 15. He spent 28 days getting used to the new place and the started his climb with about 10 other good climbers.On May 19. Alkut finally reached the top of the world, breaking the record(纪录) set last year by Xu Zhuoyuan, a 17...
[26] Maria Rosario Garcia Campelo, et al. Quality-adjusted survival with brigatinib (BRG) versus crizotinib (CRZ) in ALK-positive (ALK+) non-small cell lung cancer (NSCLC): Results from the ALTA-1L trial. 2022 ESMO, 1156P. [27] Wu YL, Dziadziuszko R, Ahn JS, et al. Alectinib...
3 Apr, 2024 Sustainability Report 2023 A Global Footprint to Deliver Global Solutions Alkegen has over 60 manufacturing facilities and 9,000-plus employees worldwide. We brought together two leading companies to take on some of the world's biggest challenges. ...
Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system (PubMed:11121404, PubMed:11387242, PubMed:16317043, PubMed:17274988, Pu...
[13]Selvaggi G, Wakelee HA, Mok T, et al. Phase III randomized study of ensartinib vs crizotinib in anaplastic lymphoma kinase (ALK) positive NSCLC patients: EXALT3. Presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer, Singapore, August 8...
4、Shimizu J, Masago K, Saito H, et al. Biomarker testing for personalized, first-line therapy in advanced nonsquamous non-small cell lung cancer patients in the real world setting in Japan: a retrospective, multicenter, observational study (the BRAVE study)[J]. Therapeutic advances in medical...
He arrived at the South Base Camp in Nepal on April 15. He spent 28 days getting used to (习惯) the new place and then started his climb with about 10 other good climbers. On May 19, Alktur finally reached the top of the world, breaking the record set last year by Xu Zhuoyuan, ...